Related Experiment Video
Updated: Jan 31, 2026
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
Kinetics and prognostic value of heparin binding protein at the ST-segment-elevation myocardial infarction
Yueying Wang1,2, Tianqi Zhu1, Wenli Zhang1
1Department of Cardiovascular Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Insights
Heparin-binding protein (HBP) shows promise as a prognostic biomarker for adverse cardiovascular events in ST-segment elevation myocardial infarction (STEMI) patients post-procedure. Elevated HBP levels at 72 hours after primary percutaneous coronary intervention (pPCI) significantly predict major adverse cardiovascular events (MACE).
Area of Science:
- Cardiology
- Biomarker Discovery
- Acute Coronary Syndromes
Background:
- ST-segment elevation myocardial infarction (STEMI) poses significant cardiovascular risk.
- Identifying reliable prognostic biomarkers is crucial for managing STEMI patients post-primary percutaneous coronary intervention (pPCI).
- Heparin-binding protein (HBP) is explored for its potential prognostic value.
Purpose of the Study:
- To investigate the role of heparin-binding protein (HBP) as a prognostic biomarker for major adverse cardiovascular events (MACE) in STEMI patients undergoing pPCI.
- To assess the correlation between HBP levels and high-sensitivity cardiac troponin I (hs-cTnI).
- To determine if HBP improves risk stratification beyond existing biomarkers.
Main Methods:
- A cohort study of 215 STEMI patients following pPCI.
- Measurement of plasma HBP and hs-cTnI at baseline and serially up to 72 hours post-pPCI.
- Median follow-up of 1.5 years to record MACE, analyzed using multivariable Cox regression and ROC curves.
Main Results:
- Plasma HBP levels significantly decreased from admission to 72 hours post-pPCI (p < 0.001).
- HBP levels at 72 hours (HBP72h) showed a moderate correlation with hs-cTnI (r=0.56).
- The highest quartile of HBP72h was independently associated with a 5-fold increased risk of MACE (HR, 5.156; p=0.0148).
- An HBP72h cut-off of 29.12 ng/mL predicted MACE with 73.0% AUC.
- Adding HBP72h to hs-cTnI significantly improved MACE prediction (NRI=0.578; p < 0.001).
Conclusions:
- Elevated HBP levels post-STEMI are linked to increased adverse cardiovascular outcomes.
- HBP72h demonstrates potential as a novel and valuable prognostic marker for STEMI patients.
- HBP may enhance risk stratification strategies in STEMI management.
Background:
This research aimed to explore the potential role of heparin-binding protein (HBP) as a prognostic biomarker for adverse events among individuals diagnosed with ST-segment elevation myocardial infarction (STEMI) who underwent primary percutaneous coronary intervention (pPCI).
Methods:
This cohort study enrolled 215 consecutive patients with STEMI following pPCI. Plasma HBP and high-sensitivity cardiac troponin I (hs-cTnI) levels were measured at admission, and at 24h, 48h, and 72h after pPCI. During a median follow-up period of 1.5 years, major adverse cardiovascular events (MACE) were recorded.
Results:
Plasma HBP levels decreased from a median of 58.04 (IQR 30.38, 106.04) ng/mL at admission to 23.80 (IQR 14.03, 44.51) ng/mL at 72 h (HBP72h) after pPCI (p < 0.001). HBP levels demonstrated a moderate correlation with hs-cTnI, particularly at 72 h post-pPCI (r = 0.56). Multivariable Cox regression analysis demonstrated that the highest HBP72h quartile was independently associated with a 5-fold increased risk of MACE during follow-up compared to the lowest quartile (hazard ratio, 5.156; 95% confidence interval, 1.380, 19.271; p = 0.0148). The ROC curve demonstrated that an HBP72h cut-off level of 29.12 ng/mL for predicting MACE had a specificity of 78.0% and a sensitivity of 61.9%, with an AUC of 0.730. Furthermore, adding HBP72h to hs-cTnI improved MACE prediction compared to hs-cTnI alone (NRI 0.578; p < 0.001).
Conclusions:
Elevated HBP levels following STEMI were associated with an increased risk of adverse outcomes and may serve as a novel and valuable prognostic marker in patients with STEMI.
Related Concept Videos
01:16Protein-Drug Binding: Mechanism and Kinetics
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
03:12Freezing Point Depression and Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
01:19Enzyme Kinetics
Scientists typically study enzyme kinetics with a fixed amount of enzyme in the controlled environment of a test tube. When more reactant, or substrate, is...
01:20Factors Affecting Protein-Drug Binding: Protein-Related Factors
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
02:18The Equilibrium Binding Constant and Binding Strength
00:23Kinetic Energy